Answers are grounded in this paper and cite their sources.
Lay Summary Despite a high approval rate, there were unnecessary delays in therapy due to prior authorizations. This study identified the impact of type of IBD, FDA-labeled indication, and dose escalations on approvals.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: